Delivery Order SPE2DB20D1100-SPE2DB25FE4Y8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Jemperli 500 mg/10 mL vials with a ceiling value of $149,037.80 and a firm fixed price structure. This contract is a non-set-aside award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a substantial $1 billion vehicle valued through December 2026. The delivery order will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at approximately $29.8K to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials. The contract was competitively awarded without set-aside provisions and carries a firm fixed-price structure, with an ultimate completion date of September 23, 2025. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. Jemperli is a specialized pharmaceutical product used in oncology treatment,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jemperli 500 mg/10 mL vials with a ceiling value of $59,615.12 and firm fixed pricing. This is a competitive award with no set-aside designation, requiring completion by September 3, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency has awarded a delivery order valued at $7,451.89 to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, due for completion by August 11, 2025. The awardee, headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jemperli 500 mg/10 mL vials with a ceiling value of $14,903.78. This is a firm fixed price delivery order under a child contract with no set-aside designation, requiring performance and completion by August 29, 2025. The drug will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. This...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Jemperli 500 mg/10 mL vials. This is a firm fixed-price delivery order with a ceiling value of $22,355.67 and an ultimate completion date of September 16, 2025. The contract represents a non-competitive set-aside award, and AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $119,230.24 to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials. This firm fixed price, non-set-aside delivery order is scheduled for completion by August 15, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal healthcare systems, particularly supporting...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $14,903.78 on April 24, 2025, for the supply of JEMPERLI 500 mg/10 ml vials. This competitive, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by May 15, 2025. The award is funded by the Department of Defense through its Medical Supply Chain organization and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Jemperli (venetoclax) 500 mg/10 mL vials. This $22,355.67 firm fixed-price delivery order carries an ultimate completion date of October 15, 2025, and represents a non-competitive, non-set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,355.67 contract is for the supply of JEMPERLI 500 MG/10 ML VIAL 10ML, a pharmaceutical product. The award is not set aside and has an ultimate completion date of July 7, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE4Y8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $29,807.56 to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials on September 5, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by September 26, 2025, with performance based in Conshohocken, Pennsylvania. Jemperli is a specialized pharmaceutical product used in oncology treatment, reflecting the Defense Logistics Agency's Medical Supply Chain's responsibility for procuring critical medications to support military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical devices to support military healthcare programs globally. The company's competitively awarded federal contracts demonstrate its capability to fulfill federal pharmaceutical and medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.8k | 9/5/25 |